Zeev's Turnips - No Politics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zeev Hed who wrote (90076)	7/2/2002 2:02:37 PM
From: Bob Biersack	of 99280

Issue comes under pressure in reaction to JP Morgan pre-market note on Genentech (DNA -3%). Firm believes that DNA's Rituxan program on rheumatoid arthritis is moving forward. JP Morgan thinks IDEC will drop development of IDEC-151 and instead work exclusively on developing Rituxan for rheumatoid arthritis. Says IDEC-151 has been associated with transient rash historically, and this side effect appears to continue to be a problem in latest drug trial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next